These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34977520)

  • 1. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
    JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey.
    Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Bottomley J; Milligan G; Piercy J; Higgins V
    Pragmat Obs Res; 2023; 14():13-27. PubMed ID: 36873793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
    O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
    JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.
    Bugianesi E; Miele L; Donnarumma G; Grau K; Mancuso M; Prasad P; Leith A; Higgins V
    Pragmat Obs Res; 2024; 15():185-200. PubMed ID: 39403308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
    Wessels DH; Rosenberg Z
    World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
    Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
    JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
    Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?
    Lazarus JV; Palayew A; Carrieri P; Ekstedt M; Marchesini G; Novak K; Ratziu V; Romero-Gómez M; Tacke F; Zelber-Sagi S; Cortez-Pinto H; Anstee QM
    JHEP Rep; 2021 Apr; 3(2):100234. PubMed ID: 33733078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis.
    Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
    JHEP Rep; 2020 Apr; 2(2):100081. PubMed ID: 32190823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.
    Rinella M; Cryer DR; Articolo A; Fisher T; Schneider J; Nadolsky K
    BMC Gastroenterol; 2022 Jul; 22(1):335. PubMed ID: 35811319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practice patterns in NAFLD and NASH: real life differs from published guidelines.
    Rinella ME; Lominadze Z; Loomba R; Charlton M; Neuschwander-Tetri BA; Caldwell SH; Kowdley K; Harrison SA
    Therap Adv Gastroenterol; 2016 Jan; 9(1):4-12. PubMed ID: 26770262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.